Age and Diabetes Mellitus Associated with Hematological Disorders and Peripheral Neuropathy in MDR-TB Patients Treated with the BPaL/M Regimen
Downloads
Introduction: Tuberculosis (TB) is a disease with a significant treatment burden. Current multidrug-resistant (MDR)-TB therapy uses the bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL/M) combination. This combination is effective with a short treatment duration. Linezolid is one of the components of the BPaL/M regimen. However, despite its effectiveness, it has side effects that impact treatment management and success. This study aimed to find the association between characteristics and comorbidities with the incidence of linezolid side effects in patients with MDR-TB treated with the BPaL/M regimen.
Methods: This was a retrospective analytic study of MDR-TB patients receiving BPaL/M combination. Data were collected from medical records and analyzed using Fisher's exact test to analyze the association between patient characteristics and comorbidities with the incidence of linezolid side effects, namely hematological disorders, peripheral neuropathy, and visual disturbances.
Results: There was no significant association between overall patient characteristics and the incidence of linezolid adverse events. However, the results of bivariate analysis showed a significant association in age >50 years old with the incidence of hematological disorders, as well as in patients who have diabetes mellitus (DM) with the incidence of peripheral neuropathy as a side effect of linezolid.
Conclusion: Monitoring of MDR-TB patients aged >50 years old and those with DM to minimize the incidence of side effects during treatment is essential. This effort is expected to support the success of the national TB control and treatment program.
World Health Organization (WHO). Global Tuberculosis Report 2024. Geneva, https://www.who.int/publications/i/item/9789240101531 (2024).
Kementerian Kesehatan Republik Indonesia. Laporan Program Penanggulangan Tuberkulosis Tahun 2022. Jakarta, https://tbindonesia.or.id/wp-content/uploads/2023/09/Laporan-Tahunan-Program-TBC-2022.pdf (2023).
Kementerian Kesehatan Republik Indonesia. Buku Pegangan Operasional: Pengobatan Tuberkulosis Resistan Obat dengan Paduan BPaL/M. Jakarta, https://www.tbindonesia.or.id/wp-content/uploads/2024/02/BUKU-PEGANGAN-OPERASIONAL-PENGOBATAN-TBC-RO-PADUAN-BaPL_M-2024.pdf (2023).
Yang Y, Hu X, Ran Y, et al. Development and Validation of a Nomogram to Predict Linezolid-Induced Thrombocytopenia in Hospitalized Adults. BMC Pharmacol Toxicol 2025; 26: 47. [Journal]
Kementerian Kesehatan Republik Indonesia. Petunjuk Teknis Penatalaksanaan Tuberkulosis Resistan Obat di Indonesia. Jakarta, https://drive.google.com/file/d/1KG58sTuUwFs6QQaSBBsHUV7K2WkwnET-/view (2024).
Greenfield A, Deja E, Lee K, et al. Linezolid and Tedizolid Adverse Effects: A Review on Serotonin Syndrome, Myelosuppression, Neuropathies, and Lactic Acidosis. Antimicrob Steward Healthc Epidemiol ASHE 2025; 5: e20. [PubMed]
Qin Y, Liu Y, Chen Z, et al. A Risk Factor-Based Predictive Model for Linezolid-Induced Anaemia: A 7-Year Retrospective Study. J Clin Pharm Ther 2021; 46: 1591-1599. [PubMed]
Thu VTA, Nhu NQ, Anh NTV, et al. Deciphering Linezolid-Induced Hematologic Toxicity: Targeting TOP2A and TOP2B via Its Primary Metabolite PNU142586. Sci Adv 2025; 11: eadt5833. [PubMed]
Azimi T, Khoshnood S, Asadi A, et al. Linezolid Resistance in Multidrug-Resistant Mycobacterium tuberculosis: A Systematic Review and Meta-Analysis. Front Pharmacol 2022; 13: 955050. [PubMed]
Rupani MP, Dave JD, Parmar VB, et al. Adverse Drug Reactions and Risk Factors for Discontinuation of Multidrug-Resistant Tuberculosis Regimens in Gujarat, Western India. Natl Med J India 2020; 33: 10–14. [PubMed]
Laarhuis SRE, Kerskes CHM, Nijziel MR, et al. Linezolid-Induced Thrombocytopenia in Patients with Renal Impairment: A Case Series, Review and Dose Advice. Drugs R D 2024; 24: 109–115. [PubMed]
Wu L, Wang XJ, Luo X, et al. Diabetic Peripheral Neuropathy based on Schwann Cell Injury: Mechanisms of Cell Death Regulation and Therapeutic Perspectives. Front Endocrinol (Lausanne) 2024; 15: 1427679. [PubMed]
Osman AAM, Seres-Bokor A, Ducza E. Diabetes Mellitus Therapy in the Light of Oxidative Stress and Cardiovascular Complications. J Diabetes Complications 2025; 39: 108941. [PubMed]
Yang Y, Zhao B, Wang Y, et al. Diabetic Neuropathy: Cutting-Edge Research and Future Directions. Signal Transduct Target Ther 2025; 10: 132. [PubMed]
Smith S, Normahani P, Lane T, et al. Prevention and Management Strategies for Diabetic Neuropathy. Life (Basel, Switzerland); 12. Epub ahead of print August 2022. [PubMed]
Jaspard M, Butel N, El Helali N, et al. Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France. Emerg Infect Dis 2020; 26: 1792-1800. [PubMed]
Jones MR, Urits I, Wolf J, et al. Drug-Induced Peripheral Neuropathy: A Narrative Review. Curr Clin Pharmacol 2020; 15: 38-48. [PubMed]
Mo K, Cao W, Lu Y, et al. Risk Factors for Linezolid-Induced Haematological Toxicity in Patients: A Retrospective Study. J Infect Dev Ctries 2024; 18: 1258-1264. [PubMed]
Handayanti L, Gunawan S. Hubungan Tingkat Pendidikan dengan Pengetahuan dalam Penggunaan Antibiotika di Lingkungan SMA/SMK Kecamatan Tambelang Kabupaten Bekasi. Tarumanagara Med J 2021; 3: 105–111. [Journal]
Adhanty S, Syarif S. Kepatuhan Pengobatan pada Pasien Tuberkulosis dan Faktor-Faktor yang Mempengaruhinya: Tinjauan Sistematis. J Epidemiol Kesehat Indones 2023; 7: 7. [Journal]
Vanderah TW. Katzung’s Basic and Clinical Pharmacology. 16th ed. McGraw Hill LLC, https://books.google.co.id/books?id=gq7BEAAAQBAJ (2023).
Padmapriyadarsini C, Solanki R, Jeyakumar SM, et al. Linezolid Pharmacokinetics and Its Association with Adverse Drug Reactions in Patients with Drug-Resistant Pulmonary Tuberculosis. Antibiotics; 12. Epub ahead of print 2023. [Journal]
Verrest L, Wilthagen EA, Beijnen JH, et al. Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review. Clin Pharmacokinet 2021; 60: 1149-1169. [PubMed]
Sukhina A, Queriault C, Roy S, et al. Malnutrition Drives Infection Susceptibility and Dysregulated Myelopoiesis that Persists after Refeeding Intervention. bioRxiv Prepr Serv Biol. Epub ahead of print April 2025. [PubMed]
Pratama NYI, Zulkarnain BS, Soedarsono, et al. Hematological Side Effect Analysis of Linezolid in MDR-TB Patients with Individual Therapy. J Basic Clin Physiol Pharmacol 2021; 32: 777-781. [PubMed]
Copyright (c) 2025 Frida Welhelmina Tako, Bintang Yinke Magdalena Sinaga, Juliandi Harahap, Rini Savitri Daulay, Jelita Siregar, Yoseph Leonardo Samodra
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.
JR (